Atara Biotherapeutics (ATRA) Net Cash Flow (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Net Cash Flow came in at -$122000.0 in Q1 2026, up 98.91% YoY from -$61334.4 in Q1 2025, and down 104.45% on a QoQ basis from $2.7 million in Q4 2025.
Atara Biotherapeutics (ATRA) Net Cash Flow (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Net Cash Flow data on file, last reported at -$122000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 98.91% year-over-year to -$122000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.6 million (up 73.52% YoY) and the FY2025 annual result came in at -$16.7 million, down 1958.45% from the prior year.
- Net Cash Flow fell to -$122000.0 in Q1 2026, from $2.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $26.6 million in Q4 2022 to a low of -$44.2 million in Q1 2023.
- A 5-year average of -$5.8 million and a median of -$3.8 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 473.73% — and 2023, when it sank 890.39%.
- Tracing ATRA's Net Cash Flow over 5 years: stood at $26.6 million in 2022, then tumbled by 246.27% to -$38.9 million in 2023, then jumped by 45.0% to -$21.4 million in 2024, then surged by 112.79% to $2.7 million in 2025, then tumbled by 104.45% to -$122000.0 in 2026.
- The last three Net Cash Flow figures came in at -$122000.0 (Q1 2026), $2.7 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -5.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.14 Mn |
| Jun 30, 2026 | -5.14 Mn |
| Mar 31, 2026 | -122,000.00 |
| Mar 31, 2026 | -122,000.00 |
| Dec 31, 2025 | 2.74 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | -11.19 Mn |
| Mar 31, 2025 | -11.19 Mn |
| Dec 31, 2024 | -21.42 Mn |
| Dec 31, 2024 | -21.42 Mn |
| Sep 30, 2024 | 15.14 Mn |
| Sep 30, 2024 | 15.14 Mn |
| Jun 30, 2024 | -3.77 Mn |
| Jun 30, 2024 | -3.77 Mn |
| Mar 31, 2024 | 9.25 Mn |
| Mar 31, 2024 | 9.25 Mn |